BioCentury | Nov 14, 2020
Product Development

ASH 2020 snapshot: efficacy data in hot emerging areas

...from cell therapy companies Atara Biotherapeutics Inc. (NASDAQ:ATRA) and Poseida Therapeutics Inc....
BioCentury | Aug 22, 2020
Emerging Company Profile

Luminary: turning cell engineering tools into therapies

...engineered cell therapy plays have non-viral transposon platforms: Poseida Therapeutics Inc....
BioCentury | Aug 19, 2020
Finance

Aug. 18 Quick Takes: Chinook fuels up for NASDAQ liftoff; plus Kymera, Poseida, Albireo

...company to go public (see “Interest in Protein Degradation Runs Hot”).Poseida tumbles after clinical holdNewly public Poseida Therapeutics Inc....
...sodium-dependent bile acid transporter member 2 BC Staff P-PSMA-101 Goofice (Brand), AJG533 (Compound #), A3309 (Compound #), elobixibat (Generic) Poseida Therapeutics Inc. Albireo...
BioCentury | Jul 18, 2020
Management Tracks

Genzyme vet Modur joins Zikani; plus Scholar Rock, Poseida, Ribon, Kiadis and more

...Kingsley will become president and CEO after CEO Nagesh Mahanthappa steps down on Aug. 1. Poseida Therapeutics Inc....
...Sawka, BioCentury Staff ViaCyte Inc. Ribon Therapeutics Inc. Innate Pharma S.A. Kiadis Pharma N.V. Zikani Therapeutics Inc. Tarsus Pharmaceuticals Inc. MaaT Pharma S.A. Neurogene Poseida Therapeutics Inc. Poseida Therapeutics AnaptysBio...
BioCentury | Jul 10, 2020
Finance

Nkarta’s $252M IPO among biggest preclinical listings ever

...among three that began trading on NASDAQ Friday. Also pricing offerings were CAR T company Poseida Therapeutics Inc....
...gains in the aftermarket (see “Data Bytes: Queue Remains Hot” ). Paul Bonanos, Associate Editor Nkarta Inc. Inventiva S.A. Poseida Therapeutics Inc....
BioCentury | Jul 9, 2020
Finance

Poseida prices $224M IPO as two other biotechs eye listings of similar size

...first time Friday, one of which is also seeking an offering upwards of $200 million. Poseida Therapeutics Inc....
...enjoyed big gains in the aftermarket (see “Data Bytes: Queue Remains Hot” ). Paul Bonanos, Associate Editor Poseida Therapeutics Inc. Nkarta...
BioCentury | Jul 8, 2020
Finance

Data Bytes: IPO queue remains hot

...indications this year and next (see “AlloVir First to Test ElevateBio’s Model” ). Meanwhile, both Poseida Therapeutics Inc....
BioCentury | Jun 26, 2020
Finance

Poseida brings in $110M ahead of IPO as more biotechs line up for NASDAQ debuts

...to line up for public market debuts (see “Biotech IPOs on NASDAQ Maintain Momentum” ). Poseida Therapeutics Inc....
...member 17 TIGIT - T cell immunoreceptor with Ig and ITIM domains Elizabeth S. Eaton, Staff Writer Poseida Therapeutics Inc. iTeos...
BioCentury | Jun 20, 2020
Finance

Forma, Repare shine in first-day performances as biotech IPOs on NASDAQ maintain momentum

...more biotechs entered the NASDAQ queue late Friday. Among them is CAR T therapeutics developer Poseida Therapeutics Inc....
BioCentury | Apr 3, 2020
Deals

Janssen takes another shot at off-the-shelf CAR Ts with Fate deal

...develop allogeneic CAR T cell therapies. The partnerships was transferred to Transposagen’s human therapeutics spinout Poseida Therapeutics Inc....
Items per page:
1 - 10 of 37
BioCentury | Nov 14, 2020
Product Development

ASH 2020 snapshot: efficacy data in hot emerging areas

...from cell therapy companies Atara Biotherapeutics Inc. (NASDAQ:ATRA) and Poseida Therapeutics Inc....
BioCentury | Aug 22, 2020
Emerging Company Profile

Luminary: turning cell engineering tools into therapies

...engineered cell therapy plays have non-viral transposon platforms: Poseida Therapeutics Inc....
BioCentury | Aug 19, 2020
Finance

Aug. 18 Quick Takes: Chinook fuels up for NASDAQ liftoff; plus Kymera, Poseida, Albireo

...company to go public (see “Interest in Protein Degradation Runs Hot”).Poseida tumbles after clinical holdNewly public Poseida Therapeutics Inc....
...sodium-dependent bile acid transporter member 2 BC Staff P-PSMA-101 Goofice (Brand), AJG533 (Compound #), A3309 (Compound #), elobixibat (Generic) Poseida Therapeutics Inc. Albireo...
BioCentury | Jul 18, 2020
Management Tracks

Genzyme vet Modur joins Zikani; plus Scholar Rock, Poseida, Ribon, Kiadis and more

...Kingsley will become president and CEO after CEO Nagesh Mahanthappa steps down on Aug. 1. Poseida Therapeutics Inc....
...Sawka, BioCentury Staff ViaCyte Inc. Ribon Therapeutics Inc. Innate Pharma S.A. Kiadis Pharma N.V. Zikani Therapeutics Inc. Tarsus Pharmaceuticals Inc. MaaT Pharma S.A. Neurogene Poseida Therapeutics Inc. Poseida Therapeutics AnaptysBio...
BioCentury | Jul 10, 2020
Finance

Nkarta’s $252M IPO among biggest preclinical listings ever

...among three that began trading on NASDAQ Friday. Also pricing offerings were CAR T company Poseida Therapeutics Inc....
...gains in the aftermarket (see “Data Bytes: Queue Remains Hot” ). Paul Bonanos, Associate Editor Nkarta Inc. Inventiva S.A. Poseida Therapeutics Inc....
BioCentury | Jul 9, 2020
Finance

Poseida prices $224M IPO as two other biotechs eye listings of similar size

...first time Friday, one of which is also seeking an offering upwards of $200 million. Poseida Therapeutics Inc....
...enjoyed big gains in the aftermarket (see “Data Bytes: Queue Remains Hot” ). Paul Bonanos, Associate Editor Poseida Therapeutics Inc. Nkarta...
BioCentury | Jul 8, 2020
Finance

Data Bytes: IPO queue remains hot

...indications this year and next (see “AlloVir First to Test ElevateBio’s Model” ). Meanwhile, both Poseida Therapeutics Inc....
BioCentury | Jun 26, 2020
Finance

Poseida brings in $110M ahead of IPO as more biotechs line up for NASDAQ debuts

...to line up for public market debuts (see “Biotech IPOs on NASDAQ Maintain Momentum” ). Poseida Therapeutics Inc....
...member 17 TIGIT - T cell immunoreceptor with Ig and ITIM domains Elizabeth S. Eaton, Staff Writer Poseida Therapeutics Inc. iTeos...
BioCentury | Jun 20, 2020
Finance

Forma, Repare shine in first-day performances as biotech IPOs on NASDAQ maintain momentum

...more biotechs entered the NASDAQ queue late Friday. Among them is CAR T therapeutics developer Poseida Therapeutics Inc....
BioCentury | Apr 3, 2020
Deals

Janssen takes another shot at off-the-shelf CAR Ts with Fate deal

...develop allogeneic CAR T cell therapies. The partnerships was transferred to Transposagen’s human therapeutics spinout Poseida Therapeutics Inc....
Items per page:
1 - 10 of 37